Pioneering the Future of Heart Health: Biograph and Caristo Diagnostics Announce First-of-its-Kind U.S. Study to Advance AI-Powered Prevention
Pioneering the Future of Heart Health: Biograph and Caristo Diagnostics Announce First-of-its-Kind U.S. Study to Advance AI-Powered Prevention
Pioneering the Future of Heart Health: Biograph and Caristo Diagnostics Announce First-of-its-Kind U.S. Study to Advance AI-Powered Prevention
Biograph, the world’s most advanced preventive health and diagnostics clinic, today announced a partnership with Caristo Diagnostics to become the first U.S. clinic to study a novel AI-based preventive cardiac marker in asymptomatic patients, by detecting coronary artery inflammation from cardiac CT scans.
This study will be exclusively available to Biograph’s Black Tier members that are clinically eligible. Study participants will receive access to Caristo’s proprietary CaRi-Heart® and CaRi-PlaqueTM technologies to evaluate whether coronary inflammation alongside plaque characterization can detect early heart disease in asymptomatic patients.
Early detection of inflammation is crucial, as it often precedes plaque buildup and provides a critical window for preventing disease. By engaging in such a partnership with Caristo, we’re better suited to position our members at the forefront of cardiac diagnostics, providing research access to a technology not yet broadly available in the U.S.
Why Inflammation Detection Matters
Current clinical pathways often fail to identify high risk patients by missing inflammatory disease activity and relying on plaque assessment alone. In fact, twice as many fatal and non-fatal cardiac events occurred in patients without obstructive plaque on coronary computed tomography angiography (CCTA), with CaRi-Heart able to identify these patients up to 10 years in advance, even in the absence of visible plaque [Lancet, 2024]. CaRi-Heart technology is a major breakthrough because it quantifies ‘invisible’ coronary inflammation on cardiac CT scans, rather than having to wait for patients to develop visible plaque. The CaRi-Heart technology is already approved for use in Europe, and this study will be its first evaluation for U.S. research applications in asymptomatic patients traditionally seen as low risk.
We selected Biograph as our first U.S. longevity focused partner because of its preventive focus, data-driven approach, and advanced imaging capabilities. With Biograph’s highly engaged patient population, this is an ideal partnership to demonstrate the impact of CaRi-Heart technology for early detection and the benefits of long-term heart health.
Study Design and Participant Experience
In the initial phase the study will enroll 100 of Biograph’s Black Tier members beginning in October. Eligible participants will complete a health history form and consultation before imaging to ensure suitability for the study. Findings are expected to corroborate Caristo’s existing studies with CaRi-Heart, in their continued efforts to make early detection available globally.
For Biograph, this initiative supports their ongoing mission to revolutionize healthcare and champion preventive approaches.
For more details on the partnership or to request enrollment in the study, get in touch at info@biograph.com
Biograph
For press inquiries, get in touch at press@biograph.com
Biograph is on a mission to drive meaningful advances in human healthspan and lifespan. We're not simply focused on helping you live longer. We're focused on making every year the best it can be. Because how well you live is as important as how long you live. With an emphasis on human centered design, we've created an unparalleled clinical facility to defy industry norms. We are committed to giving each of our Members exceptional service throughout their Biograph journey. We continuously incorporate new research into our method to remain on the cutting edge of medicine.
Caristo Diagnostics
For more information, visit caristo.com.
Caristo Diagnostics (www.caristo.com) is a global leader in AI-powered heart disease detection. A spinout from the University of Oxford, Caristo’s award-winning technology is transforming cardiovascular care by identifying hidden heart attack risks before symptoms appear. Caristo already received FDA 510(k) clearance for its CaRi-Plaque technology, which quantifies coronary plaque and stenosis based on CCTA scans. Backed by leading hospitals and scientists, Caristo is on a mission to save lives through early detection and personalized prevention.
Biograph, the world’s most advanced preventive health and diagnostics clinic, today announced a partnership with Caristo Diagnostics to become the first U.S. clinic to study a novel AI-based preventive cardiac marker in asymptomatic patients, by detecting coronary artery inflammation from cardiac CT scans.
This study will be exclusively available to Biograph’s Black Tier members that are clinically eligible. Study participants will receive access to Caristo’s proprietary CaRi-Heart® and CaRi-PlaqueTM technologies to evaluate whether coronary inflammation alongside plaque characterization can detect early heart disease in asymptomatic patients.
Early detection of inflammation is crucial, as it often precedes plaque buildup and provides a critical window for preventing disease. By engaging in such a partnership with Caristo, we’re better suited to position our members at the forefront of cardiac diagnostics, providing research access to a technology not yet broadly available in the U.S.
Why Inflammation Detection Matters
Current clinical pathways often fail to identify high risk patients by missing inflammatory disease activity and relying on plaque assessment alone. In fact, twice as many fatal and non-fatal cardiac events occurred in patients without obstructive plaque on coronary computed tomography angiography (CCTA), with CaRi-Heart able to identify these patients up to 10 years in advance, even in the absence of visible plaque [Lancet, 2024]. CaRi-Heart technology is a major breakthrough because it quantifies ‘invisible’ coronary inflammation on cardiac CT scans, rather than having to wait for patients to develop visible plaque. The CaRi-Heart technology is already approved for use in Europe, and this study will be its first evaluation for U.S. research applications in asymptomatic patients traditionally seen as low risk.
We selected Biograph as our first U.S. longevity focused partner because of its preventive focus, data-driven approach, and advanced imaging capabilities. With Biograph’s highly engaged patient population, this is an ideal partnership to demonstrate the impact of CaRi-Heart technology for early detection and the benefits of long-term heart health.
Study Design and Participant Experience
In the initial phase the study will enroll 100 of Biograph’s Black Tier members beginning in October. Eligible participants will complete a health history form and consultation before imaging to ensure suitability for the study. Findings are expected to corroborate Caristo’s existing studies with CaRi-Heart, in their continued efforts to make early detection available globally.
For Biograph, this initiative supports their ongoing mission to revolutionize healthcare and champion preventive approaches.
For more details on the partnership or to request enrollment in the study, get in touch at info@biograph.com
Biograph
For press inquiries, get in touch at press@biograph.com
Biograph is on a mission to drive meaningful advances in human healthspan and lifespan. We're not simply focused on helping you live longer. We're focused on making every year the best it can be. Because how well you live is as important as how long you live. With an emphasis on human centered design, we've created an unparalleled clinical facility to defy industry norms. We are committed to giving each of our Members exceptional service throughout their Biograph journey. We continuously incorporate new research into our method to remain on the cutting edge of medicine.
Caristo Diagnostics
For more information, visit caristo.com.
Caristo Diagnostics (www.caristo.com) is a global leader in AI-powered heart disease detection. A spinout from the University of Oxford, Caristo’s award-winning technology is transforming cardiovascular care by identifying hidden heart attack risks before symptoms appear. Caristo already received FDA 510(k) clearance for its CaRi-Plaque technology, which quantifies coronary plaque and stenosis based on CCTA scans. Backed by leading hospitals and scientists, Caristo is on a mission to save lives through early detection and personalized prevention.
Biograph, the world’s most advanced preventive health and diagnostics clinic, today announced a partnership with Caristo Diagnostics to become the first U.S. clinic to study a novel AI-based preventive cardiac marker in asymptomatic patients, by detecting coronary artery inflammation from cardiac CT scans.
This study will be exclusively available to Biograph’s Black Tier members that are clinically eligible. Study participants will receive access to Caristo’s proprietary CaRi-Heart® and CaRi-PlaqueTM technologies to evaluate whether coronary inflammation alongside plaque characterization can detect early heart disease in asymptomatic patients.
Early detection of inflammation is crucial, as it often precedes plaque buildup and provides a critical window for preventing disease. By engaging in such a partnership with Caristo, we’re better suited to position our members at the forefront of cardiac diagnostics, providing research access to a technology not yet broadly available in the U.S.
Why Inflammation Detection Matters
Current clinical pathways often fail to identify high risk patients by missing inflammatory disease activity and relying on plaque assessment alone. In fact, twice as many fatal and non-fatal cardiac events occurred in patients without obstructive plaque on coronary computed tomography angiography (CCTA), with CaRi-Heart able to identify these patients up to 10 years in advance, even in the absence of visible plaque [Lancet, 2024]. CaRi-Heart technology is a major breakthrough because it quantifies ‘invisible’ coronary inflammation on cardiac CT scans, rather than having to wait for patients to develop visible plaque. The CaRi-Heart technology is already approved for use in Europe, and this study will be its first evaluation for U.S. research applications in asymptomatic patients traditionally seen as low risk.
We selected Biograph as our first U.S. longevity focused partner because of its preventive focus, data-driven approach, and advanced imaging capabilities. With Biograph’s highly engaged patient population, this is an ideal partnership to demonstrate the impact of CaRi-Heart technology for early detection and the benefits of long-term heart health.
Study Design and Participant Experience
In the initial phase the study will enroll 100 of Biograph’s Black Tier members beginning in October. Eligible participants will complete a health history form and consultation before imaging to ensure suitability for the study. Findings are expected to corroborate Caristo’s existing studies with CaRi-Heart, in their continued efforts to make early detection available globally.
For Biograph, this initiative supports their ongoing mission to revolutionize healthcare and champion preventive approaches.
For more details on the partnership or to request enrollment in the study, get in touch at info@biograph.com
Biograph
For press inquiries, get in touch at press@biograph.com
Biograph is on a mission to drive meaningful advances in human healthspan and lifespan. We're not simply focused on helping you live longer. We're focused on making every year the best it can be. Because how well you live is as important as how long you live. With an emphasis on human centered design, we've created an unparalleled clinical facility to defy industry norms. We are committed to giving each of our Members exceptional service throughout their Biograph journey. We continuously incorporate new research into our method to remain on the cutting edge of medicine.
Caristo Diagnostics
For more information, visit caristo.com.
Caristo Diagnostics (www.caristo.com) is a global leader in AI-powered heart disease detection. A spinout from the University of Oxford, Caristo’s award-winning technology is transforming cardiovascular care by identifying hidden heart attack risks before symptoms appear. Caristo already received FDA 510(k) clearance for its CaRi-Plaque technology, which quantifies coronary plaque and stenosis based on CCTA scans. Backed by leading hospitals and scientists, Caristo is on a mission to save lives through early detection and personalized prevention.